Appointments and Affiliations
Ph.D., University of California, Biostatistics, 2004.
B.S, University of Texas, Statistics, 1997.
- Design and analysis of clinical trials for vaccines against infectious diseases
- Statistical methods in immunological assay validation and evaluation
- Statistical methods in equivalence testing
- Immune correlates of protection
2010-2011: Director, Data Analysis Unit, Statistical Center for HIV/AIDS Research and Prevention
2004-2009: Staff Scientist, Statistical Center for HIV/AIDS Research and Prevention.
2004: Bioinformatics Specialist, The Salk Institute, Plant Biology Laboratory.
2001-2003: Statistical Consultant, University of California, Los Angeles, Array Data Analysis Group, Department of Biostatistics.
2002: Research Assistant, University of California, Los Angeles, Department of Human Genetics and Department of Biostatistics.
2000-2002: Research Assistant, University of California, Los Angeles, Department of Biostatistics.
1999: Research Assistant, University of Texas at Austin, Department of Civil Engineering.
Collaboration of AIDS Vaccine Discovery (CAVD), Head, Biostatistics Collaboration, Appointed: 2011
Statistical Center for HIV/AIDS Research and Prevention, HVTN SDMC Leadership Team
Member, Appointed: 2011
Member, Appointed: 2011
2009: Invited member, FHCRC/UW delegation to China CDC, Delegation Chairs: Dr. Lee Hartwell
2008: Invited member, FHCRC/UW delegation to China CDC, Beijing, Delegation Chairs: Drs. Tuofu Zhu & Steve Self
2004-present: International Society for Computational Biology
2003-present: American Statistical Association
Honors and Awards
2002-2003: Dissertation Fellowship, Graduate Division at UCLA
2002-2003: Phi Beta Kappa Fellowship (PBK)
2002: Raymond D. Goodman Scholarship, School of Public Health at UCLA
2000: Young Investigator Award, Transplant 2000
2000: School of Public Health Travel Grant, UCLA
1999: George R. Jordan, Actuarial Science Scholarship, UT Austin
2010-present: Editorial Board Member, Journal of AIDS & Clinical Research
- Bill & Melinda Gates Foundation, Vaccine Immunology Statistical Center (VISC), Head of Biostatistical Unit, (PI: Steven Self), 2011-2016.
- NIH/NIAID: Leadership for HIV/AIDS Clincal Trials Networks: HIV Vaccine Trials Network, (PI: Steven Self), 2006-2013.
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.. Statistics in medicine. 35(21):3745-59.. 2016.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65.. 2016.
Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.. Journal of immunology (Baltimore, Md. : 1950). 197(12):4603-4612.. 2016.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
New clinical trial designs for HIV vaccine evaluation.. Current opinion in HIV and AIDS. 8(5):436-41.. 2013.
Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.. 2013.
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266.. 2012.
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67.. 2012.
Comparability and reproducibility of biomedical data.. Briefings in bioinformatics.. 2012.
Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error.. Statistics in medicine. 31(28):3748-59.. 2012.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86.. 2012.
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.. Journal of immunological methods. 375(1-2):57-67.. 2012.
HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable.. Journal of immunology (Baltimore, Md. : 1950). 187(6):3391-3401.. 2011.
Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.. Journal of acquired immune deficiency syndromes (1999). 58(3):248-52.. 2011.
Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549.. 2011.
Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study).. Journal of acquired immune deficiency syndromes (1999). 57(3):238-244.. 2011.
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.. The Journal of infectious diseases. 203(8):1165-73.. 2011.
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.. PloS one. 5(12):e14330.. 2010.
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.. PloS one. 5(2):e9310.. 2010.